Objectives: To describe the change in the incidence rates of primary and secondary focal segmental glomerulosclerosis (FSGS) from 1994 through 2013 in Olmsted County, Minnesota, and to identify the clinical and biopsy characteristics that distinguish primary from secondary FSGS. Patients and Methods: Olmsted County adult residents with native kidney biopsy from January 1, 1994, through December 31, 2013, and FSGS as the only glomerulopathy were identified. The clinical and pathologic characterstics of primary and secondary FSGS were described and compared, and incidence rates were calculated. 
T he incidence of focal segmental glomerulosclerosis (FSGS) in adults has increased during the past few decades. This temporal trend has been observed in large metropolitan areas and in small rural communities, regardless of racial and ethnic background (Table 1) . [1] [2] [3] [4] [5] [6] [7] Now, FSGS accounts for 20% to 40% of all biopsy-proven glomerular diseases in adults. [3] [4] [5] [6] [7] [8] However, the previous studies have important limitations. First, most studies reported trends in relative disease frequencies in biopsied patients rather than true population-based incidence rates of FSGS. This approach can result in misleading conclusions because a change in the proportion of one disease automatically affects the proportions of other diseases. Furthermore, as the referral population for kidney biopsy changes over time, so do the relative frequencies of different diseases. Another important limitation in the previous studies is the approach of reporting FSGS as a single disease entity. [2] [3] [4] [5] [6] [7] [8] We now know that FSGS is a histologic pattern of injury that characterizes a broad spectrum of diseases with different pathophysiologies. Primary FSGS is presumed to be due to a circulating permeability factor diffusely toxic to podocytes, which may respond to immunosuppressive treatment. 9 On the other hand, secondary FSGS is a response to reduction in the number of functioning nephrons (eg, unilateral renal agenesis)
or from an abnormal stress on initially normal nephrons. 9 The treatment is centered around unloading the pressure on glomeruli using renin-angiotensin-aldosterone system (RAAS) inhibition.
To better evaluate the incidence of FSGS, it is critical to distinguish primary FSGS from secondary forms in a population-based study. Olmsted County in Minnesota is particularly well suited to perform a population-based study of glomerular diseases. The aim of this study was to describe the change in the incidence rates of primary and secondary FSGS from 1994 through 2013 in Olmsted County 
METHODS

Study Population
The population of Olmsted County and their clinical care by nearly all providers are enumerated through the Rochester Epidemiology Project. 10 This study included all adult residents of Olmsted County who underwent native kidney biopsy between January 1, 1994, and December 31, 2013, at Mayo Clinic in Rochester, Minnesota. Mayo Clinic was the only regional center in Olmsted County that performed and read kidney biopsies in the study period.
Pathology Characteristics
The following data were abstracted from kidney biopsy reports: pathologic diagnosis, number of glomeruli and globally sclerotic glomeruli, arteriosclerosis, arteriolar hyalinosis, and interstitial fibrosis and tubular atrophy. We identified patients with FSGS as the only glomerulopathy, defined as the presence of segmental sclerotic lesions on biopsy. Patients with only focal global sclerosis were excluded. For each patient with FSGS, available light microscopy slides and electron micrographs were reviewed by 2 renal pathologists (M.P.A. and S.S.) blinded to the clinical data. Each biopsy sample was assigned a Columbia classification. 11 Because the first histologic manifestation of recurrent primary FSGS after kidney transplant is widespread foot process effacement (FPE), we initially divided the patients according to the degree of FPE. Patients were classified into those with diffuse FPE (!80%) vs those with limited FPE (<80%). The cutoff value of 80% was chosen based on previous work showing that patients with nephrotic syndrome (NS), FSGS lesions, and no identifiable risk factors for secondary FSGS had FPE in the range of 80% to 100%. 12 The degree of FPE was evaluated on electron microscope sections of at least 2 nonsclerosed glomeruli. Quantification of FPE was based on the loops examined: 100%, all loops showed complete effacement; 90%, 1 of 10 loops did not show complete effacement; 80%, 2 of 10 loops did not show complete effacement. If foot processes were preserved, it was considered limited FPE. Arteriosclerosis and arteriolar hyalinosis were graded on a scale from 0 to 3 (0¼none, 1¼mild, 2¼moderate, and 3¼severe). Interstitial fibrosis and tubular atrophy was classified into 0% to 5% (none to minimal), 6% to 25% (mild), and greater than 25% (moderate to severe). 13 
Clinical Characteristics
Baseline clinical characteristics were abstracted from the episode of care closest to the time of kidney biopsy and included age, sex, race, hypertension, diabetes mellitus, vascular disease (composite of coronary artery disease, stroke, and peripheral arterial disease), dyslipidemia, use of an angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blockers, statins, systolic and diastolic blood pressure, serum creatinine level, serum albumin level, total cholesterol level, and 24-hour proteinuria. When timed urine collection was not available to quantify proteinuria, the protein to creatinine or protein to osmolality ratio on a spot urine sample was used to estimate daily proteinuria. Nephrotic syndrome at baseline was defined as proteinuria of at least 3.5 g/24 h and a serum albumin level of 3.5 g/dL or less (to convert to g/L, multiply by 10).
14 Follow-up data included treatment initiated after the diagnosis of FSGS, serum creatinine level, and proteinuria trends after the biopsy date, last visit date, and, when applicable, death and development of end-stage renal disease (ESRD) dates.
FSGS Classification
The identified patients with FSGS were classified as having diffuse FPE (!80%) or limited FPE (<80%). We further classified patients with diffuse FPE into those with identifiable causes for FPE and those without. Primary FSGS was defined as diffuse FPE without an identifiable cause. Patients who had limited FPE or who had diffuse FPE but an identifiable cause for FPE were classified as having secondary FSGS. Patients who did not have electron micrographs to review were classified as having primary vs secondary FSGS based on their clinical presentation.
Statistical Analyses
The incidence rates and 95% CIs (per 100,000 person-years) for native kidney biopsies, FSGS, and other glomerulopathies were calculated for the entire study period as well as separately for 1994 to 2003 and 2004 to 2013. Rates were calculated using the exact method assuming a Poisson distribution and were adjusted for age and sex using the US 2010 Decennial Census. Poisson regression models were used to calculate the change in incidence rate per 5 years from 1994 to 2013. P values were calculated using the Fisher exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. Baseline characteristics, FSGS subtypes, and treatment approaches were described for patients with primary FSGS and secondary FSGS. Statistical analysis was performed using SAS software and JMP Pro version 10.0.0 (SAS Institute Inc). A P<.05 was considered statistically significant. This study was approved by the institutional review board at Mayo Clinic.
RESULTS
A total of 370 adult patients underwent native kidney biopsy from 1994 through 2013, of which 281 had glomerular diseases as the primary diagnosis.
Of those with glomerular diseases, 46 (16%) had FSGS as the only glomerulopathy (Supplemental Figure 1 , available online at http://www. mayoclinicproceedings.org). Twelve cases of FSGS occurred in the first decade (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) and 34 in the second decade (2004-2013). Available electron micrographs were reviewed to classify patients according to the degree of FPE. Four patients did not have electron micrographs to review. Of the remaining 42 patients, 11 had diffuse FPE without an identifiable cause, 27 had limited FPE, and 4 had diffuse FPE due to an identifiable cause, including preeclampsia (n¼1), syndromic presentation suspicious for genetic FSGS (n¼1), and the presence of ischemic glomeruli only on electron micrographs (n¼2). Tables 2 and 3 compare the clinical and biopsy characteristics of patients with diffuse FPE without identifiable cause and patients with limited FPE. Compared with Figure 2 , available online at http://www. mayoclinicproceedings.org).
Based on these results, we classified the 11 patients who presented with diffuse FPE without identifiable cause and NS as having primary FSGS. The remaining 31 patients with limited FPE or diffuse FPE due to an identifiable cause were classified as having secondary FSGS. This left 4 patients who did not have electron micrographs to review. These 4 patients were classified based on their clinical presentation. One patient presented with sudden-onset severe NS, was treated with prednisone without significant reduction in proteinuria, and progressed to ESRD. This patient was classified as having primary FSGS. The other 3 patients did not have NS on presentation and had risk factors for secondary FSGS (reflux nephropathy, longstanding hypertension, and long-term use of lithium) and were classified as having secondary FSGS. Thus, further analysis was based on 12 patients with primary FSGS and 34 patients with secondary FSGS (Supplemental Figure 1) . Figure 4 (available online at http://www.mayoclinicproceedings.org). Although the rate of total FSGS increased during the study period, the proportion of primary FSGS remained relatively stable at approximately 25% (Figure) . In all biopsied patients, serum creatinine and proteinuria levels at the time of biopsy were not significantly different across the 2 decades (median biopsy creatinine level,1.6 vs 1.8 mg/dL; P¼.48; and median proteinuria, 2.1 vs 1.6 g/d; P¼.17).
In patients with secondary FSGS, a risk factor for adaptive FSGS could be identified in 13 of the 34 patients (38%). Risk factors included reflux and obstructive nephropathy (n¼3), unilateral nephrectomy or dysplastic kidney (n¼2), renal artery stenosis (n¼1), preeclampsia (n¼2), pamidronate use (n¼1), and chronic lithium use (n¼1). Underlying genetic disease was diagnosed in 3 patients: INF2 mutation (n¼1) and thin basement membrane disease (n¼2). There were no significant differences in clinical and biopsy characteristics of patients with identifiable secondary FSGS risk factors and patients without identifiable secondary risk factors (Supplemental Table 1 , available online at http://www.mayoclinicproceedings.org).
Of the 12 patients with primary FSGS, 4 were treated with immunosuppression (3 with corticosteroids alone and 1 with corticosteroids followed by cyclosporine after NS relapsed) (Supplemental Table 2 , available online at http://www. mayoclinicproceedings.org). The reasons for not treating the other 8 patients with immunosuppression included improvement in proteinuria with RAAS blockade (n¼3), the treating physician's impression that FSGS was secondary (n¼3), and a low baseline estimated glomerular filtration rate (n¼2). Eventually, 3 patients (25%) with primary FSGS progressed to ESRD over an average of 6 months after the biopsy date: 1 patient treated with prednisone but who continued to have NS and 2 patients treated conservatively. Of the 34 patients with secondary FSGS, 2 were treated with immunosuppression. One patient had proteinuria of 1.2 g/d after treatment with ACEi, and the treating physician elected a trial of prednisone for 3 months, after which proteinuria stabilized to approximately 0.6 g/d. The other patient had an initial improvement in proteinuria after starting ACEi therapy but then it increased back to 3.4 g/d. A corticosteroid trial for 3 months followed by cyclosporine use led to proteinuria persisting at approximately 2 g/d. Eventually, 11 patients (34%) with secondary FSGS progressed to ESRD over an average of 4.5 years from the biopsy date. Only a small number of patients underwent kidney transplant. Two patients with primary FSGS received a kidney transplant and had allograft survival greater than 10 years, with no FSGS recurrence. Two patients with secondary FSGS received a kidney transplant within the past 3 years and did not have evidence of FSGS recurrence on allograft biopsies.
DISCUSSION
The salient observation of this population-based study is that the incidence rates of combined primary and secondary FSGS increased during the past 2 decades, and the proportions of primary and secondary FSGS remained stable.
The first question is whether this is a true rise in disease incidence or simply better and earlier identification of patients. The rate of native kidney biopsy adjusted for the change in the population increased by 56% during the study period. This increase likely reflects improved biopsy techniques and lower complication rates, making the nephrologist more comfortable proceeding with a kidney biopsy. 15 Although this increase in biopsies may contribute to better identification of patients, the incidence rate of FSGS increased by more than 130% over the same period. Furthermore, serum creatinine and proteinuria levels at the time of biopsy were not significantly different during the study period, which is contrary to the notion that nephrologists are performing biopsies on patients with milder forms of disease.
The increasing incidence of FSGS has been a consistent observation in older and recent biopsy studies. [1] [2] [3] [4] [5] [6] [7] In some studies, this increase was observed in black patients, in particular, 2, 3 whereas other studies revealed an increased incidence of FSGS across all races. We report a significant rise in the incidence of FSGS in a population that is predominantly white, indicating that factors other than race are responsible. Although changes in lifestyle and diet could explain a rise in FSGS caused by obesity, the rise in primary FSGS remains unexplained.
Distinguishing primary from secondary FSGS remains a big challenge. The common denominator in all types of FSGS is the presence of podocyte injury as the initiating event. Podocytes can be damaged by a variety of mechanisms, from a nonmechanical insult (eg, immunologic), to mechanical stress, to genetic mutations disrupting endogenous components. Whatever the type of stress, the podocytes initially respond with loss of the interdigitating foot process pattern, ie, FPE. Whether FPE is a coordinated process to increase the chances of cell survival or merely a sign of derangement of a highly organized system remains controversial. 16 When the podocyte injury is initiated by intensified mechanical stress due to glomerular hyperfiltration and hypertrophy, secondary FSGS results. In this situation, FPE is typically focal because shear stress is unevenly distributed along the glomerular capillaries, decreasing toward the end of the network. 17 These patients typically do not develop NS, although proteinuria may be in the nephrotic range. 18, 19 On the other hand, in primary FSGS a putative circulating permeability factor causes generalized podocyte dysfunction, and the resulting cytoskeletal dysregulation ensues in diffuse FPE. The evidence supporting this presumptive toxic circulating factor includes the rapid recurrence of primary FSGS in transplanted kidneys that can be treated with early initiation of plasmapheresis, [20] [21] [22] [23] and the observation that explanting and retransplanting kidneys with recurrent primary FSGS into patients without FSGS leads to resolution of proteinuria and the histologic pattern of injury to podocytes. 24, 25 Transient proteinuria in infants born to mothers with primary FSGS has been reported, also suggesting the transfer of permeability factors across the placenta. 26 Finally, the central feature of primary FSGS is the diffuse FPE that if left untreated can progress to NS in most patients. This diffuse pattern supports the notion that systemic rather than local factors drive podocyte injury. Unlike in secondary FSGS, RAAS blockade is ineffective in reducing proteinuria in primary FSGS. 27 Taken together, from a pathophysiologic point of view it can be derived that the extent of FPE is determined by the underlying mechanism of podocyte injury. We, therefore, classified patients according to the degree of FPE in this study. A morphometric analysis of foot process width excluding patients with familial forms of FSGS found broader foot processes in patients with primary FSGS compared with those with secondary FSGS. 28 Consequently, the degree of FPE can be used as a tool to help distinguish primary from secondary FSGS. If this is true, patients with widespread FPE should have significant proteinuria and hypoalbuminemia due to the severe and diffuse impairment in the filtration barrier. Indeed, we found an almost perfect correlation between the presence of diffuse FPE and having NS. Because electron microscopy may not be routinely available to all practicing nephrologists, we propose the use of NS as a surrogate marker for diffuse FPE. Indeed, the area under the receiver operating characteristic curve using the presence of NS to predict the presence of FPE of 80% or greater was 0.85. However, this is only applicable to patients not treated with immunosuppressive therapy because such treatment can alter FPE degree and NS if instituted before obtaining the biopsy. Although the presence of NS was commensurate with diffuse FPE, the correlation between proteinuria alone and the degree of FPE was less robust. Another study also revealed a poor correlation between FPE and proteinuria in patients with minimal change disease and IgA nephropathy. 29 Genetic cases of FSGS pose a challenge to this approach. It is established that infants and children with genetic FSGS usually present with explosive NS, 30 but this is not the case in adults. 31 Some adult patients with genetic FSGS may present with diffuse FPE and NS, and others may have focal FPE. In fact, at Mayo Clinic, we have seen siblings expressing the same mutation but presenting with variable degrees of FPE and proteinuria. Other external factors may modulate the response of the podocytes to the underlying mutation. Thus, it is important to consider a genetic mutation when patients with presumed primary FSGS seem to be resistant to immunosuppressive therapy or when patients present in an unusual way (eg, diffuse FPE but no NS). 9 Genetic mutations should also be considered in patients with secondary FSGS without identifiable risk factors. Current diagnostic tools failed to identify a specific risk factor for secondary FSGS in a substantial number of patients (>50%) despite having histopathologic and clinical features suggestive of secondary FSGS. Some of these patients may have undiagnosed genetic forms of FSGS, which may be uncovered by using next-generation sequencing. 32 It is also important to point out that light microscopy features and Columbia classification do not help distinguish primary from secondary FSGS with certainity. In our experience, although perihilar segmental sclerosis is more likely to be seen in secondary FSGS, it is also noted in primary FSGS. 12 A perihilar pattern of injury does not exclude primary FSGS.
This study has important strengths. To our knowledge, this is the first population-based study to report incidence rates of primary and secondary FSGS separately rather than reporting relative disease frequencies or reporting FSGS as a single disease entity. Although we had a small number of patients, we had complete clinical data and were able to review the biopsy slides and electron micrographs to quantify FPE and exclude patients with focal global glomerulosclerosis only. The comprehensive medical records linkage system has allowed Olmsted County to contribute to some of the best epidemiologic studies published to date.
This study has limitations. The Olmsted County population is largely white, limiting generalizability of the results to other races. Given the retrospective nature of this study, we had limited data about potential risk factors for developing FSGS, including medications and infections. Also, genetic testing was not routinely performed. Genetic FSGS may be mistakenly classified as primary FSGS given the degree of proteinuria and diffuse FPE associated with certain genetic defects. Nevertheless, current guidelines do not recommend routine screening of adult patients without a family history of renal disease. 33 
CONCLUSION
Although the incidence rate of FSGS is increasing, the majority of cases are secondary, not primary, FSGS, while the ratio of primary and secondary FSGS has remained stable during the past 2 decades. The increasing rate of kidney biopsy may contribute to this observed increase in the incidence of FSGS, but it does not explain the whole picture. Distinguishing primary from secondary FSGS remains a challenge in the absence of a serologic marker. Until a specific criterion standard biomarker test for diagnosing primary FSGS is developed, using a combination of clinical features (NS) and pathologic features (diffuse FPE), in the absence of any identifiable cause, provides the best approach to distinguishing primary from secondary FSGS.
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